

September 25th, 2025

Subject: Announcement Public Reimbursement for LEQVIO® HeFH in Quebec

Dear Health Care Provider,

We are pleased to share that effective Sept 25th, 2025, LEQVIO® (inclisiran) is listed on the Liste des Médicaments de la RAMQ for Heterozygous familial hypercholesterolemia (HeFH).

As a reminder LEQVIO® is indicated as an adjunct to lifestyle changes, including diet, to further reduce low-density lipoprotein cholesterol (LDL-C) level in adults with the following conditions who are on maximally tolerated dose of a statin, with or without other LDL-C lowering therapies:

- Heterozygous familial hypercholesterolemia (HeFH), or
- Non-familial hypercholesterolemia with atherosclerotic cardiovascular disease

Patients meeting the following criteria for reimbursement may now access LEQVIO® through RAMQ¹:

- confirmed diagnosis of HeFH by genotyping or phenotyping (i.e. CCS definition, Simon Broome (possible or definite) or Dutch Lipid Score ≥ 6 (i.e., probably or definite))
- patients are on maximally tolerated dose of statins in combination with ezetimibe who are inadequately controlled as follows:
 - for primary prevention of cardiovascular events:
 - Have not had a reduction of at least 50% in LDL-C concentration from baseline and whose LDL-C is not < 2.5 mmol/L.
 - for secondary prevention of cardiovascular events:
 - Has not attained an LDL-C < 1.8 mmol/L.

The PSP team is here to help navigate the reimbursement process and help with any additional reimbursement requests. If you require any further details or clarification regarding this communication, please contact the LEQVIO® Assist Patient Support Program at:

Tel: 1-833-928-4055

Email: leqvio.assist@novartis.com

Sincerely,

Caroline Soueidy
Commercial Director